press release

June 13, 2022, 8:00 a.m. EDT

Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 13, 2022 (PRNewswire via COMTEX) -- PR Newswire

SAN DIEGO, June 13, 2022

SAN DIEGO, June 13, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS -1.17% , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first healthy volunteer in the Phase 1 SAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

"The initiation of the clinical trial of RGLS8429 with the dosing of the first subject marks another important milestone for our program targeting the treatment of ADPKD" said Jay Hagan, President and Chief Executive Officer of Regulus Therapeutics. "There is a significant unmet need for patients with this disease and we look forward to the continued advancement of this trial."

The Company is conducting a Phase 1 SAD study in healthy volunteers to assess safety, tolerability, and pharmacokinetics of RGLS8429. Following the SAD study, the Company plans to initiate a Phase 1b multiple ascending dose (MAD) study to assess safety, tolerability, and pharmacokinetics of RGLS8429 in adult patients with ADPKD, and to evaluate the efficacy of RGLS8429 treatment across three different dose levels including changes in polycystins, cystic kidney volume (htTKV), and overall kidney function.

About ADPKD Autosomal Dominant Polycystic Kidney Disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60. Approximately 160,000 individuals are diagnosed with the disease in the United States alone, with an estimated global prevalence of 4 to 7 million.

About RGLS8429 RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound.

Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS -1.17% is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's clinical trials involving RGLS8429 for the treatment of autosomal dominant polycystic kidney disease, including the planned initiation of clinical trials involving ADPKD patients and potential outcome of such clinical studies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Cision
View original content to download multimedia: https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-first-subject-dosed-in-phase-1-single-ascending-dose-sad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301566144.html

SOURCE Regulus Therapeutics Inc.

COMTEX_408609101/2454/2022-06-13T08:00:11

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2022 PR Newswire. All rights reserved

/zigman2/quotes/202916513/composite
US : U.S.: Nasdaq
$ 1.69
-0.02 -1.17%
Volume: 15,819
Dec. 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.80 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/202916513/composite
US : U.S.: Nasdaq
$ 1.69
-0.02 -1.17%
Volume: 15,819
Dec. 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.80 million
Rev. per Employee
N/A
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.